Short answer
MBX Biosciences, Inc. (MBX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$62M
- −188.7% YoY · −68.3% QoQ
- EPS (diluted)
- −$1.29
- −104.8% YoY · −63.3% QoQ
Source: XBRL data from the MBX Biosciences, Inc. (MBX) Q3 2026 10-Q on SEC EDGAR. USD.
MBX Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $0, unchanged YoY, no approved products or sales
- Net loss $62.4M vs $21.6M YoY, operating margin not applicable
- R&D $32.0M vs $19.3M, canvuparatide largest program at $13.6M
- Cash, equivalents and securities $481.6M vs $373.7M; operating cash use $77.7M
- Outlook: funding projected into 2029, expenses rising with Phase 3 and obesity pipeline development
Risk Factors
- No material changes to previously disclosed risk factors in the 2025 Annual Report
- Business, prospects, operating results and financial condition could suffer materially
- Common-stock trading price could decline, risking partial or total investment loss
- Additional risks currently unknown or deemed immaterial could adversely affect the business
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MBX Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.